Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data.

Martin A, Scahill L, Anderson GM, Aman M, Arnold LE, McCracken J, McDougle CJ, Tierney E, Chuang S, Vitiello B.

Am J Psychiatry. 2004 Jun;161(6):1125-7.

PMID:
15169706
2.

[Metabolic side effects of risperidone in early onset schizophrenia].

Goeb JL, Marco S, Duhamel A, Kechid G, Bordet R, Thomas P, Delion P, Jardri R.

Encephale. 2010 Jun;36(3):242-52. doi: 10.1016/j.encep.2009.10.008. French.

PMID:
20620267
3.

Risperidone-induced weight gain in referred children with autism spectrum disorders is associated with a common polymorphism in the 5-hydroxytryptamine 2C receptor gene.

Hoekstra PJ, Troost PW, Lahuis BE, Mulder H, Mulder EJ, Franke B, Buitelaar JK, Anderson GM, Scahill L, Minderaa RB.

J Child Adolesc Psychopharmacol. 2010 Dec;20(6):473-7. doi: 10.1089/cap.2009.0071.

PMID:
21186965
4.

Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial.

Aman M, Rettiganti M, Nagaraja HN, Hollway JA, McCracken J, McDougle CJ, Tierney E, Scahill L, Arnold LE, Hellings J, Posey DJ, Swiezy NB, Ghuman J, Grados M, Shah B, Vitiello B.

J Child Adolesc Psychopharmacol. 2015 Aug;25(6):482-93. doi: 10.1089/cap.2015.0005.

PMID:
26262903
5.

Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism.

Hellings JA, Zarcone JR, Crandall K, Wallace D, Schroeder SR.

J Child Adolesc Psychopharmacol. 2001 Fall;11(3):229-38.

PMID:
11642473
6.

Risperidone-associated weight gain in children and adolescents: a retrospective chart review.

Martin A, Landau J, Leebens P, Ulizio K, Cicchetti D, Scahill L, Leckman JF.

J Child Adolesc Psychopharmacol. 2000 Winter;10(4):259-68.

PMID:
11191686
7.

Risperidone associated weight, leptin, and anthropometric changes in children and adolescents with psychotic disorders in early treatment.

Maayan LA, Vakhrusheva J.

Hum Psychopharmacol. 2010 Mar;25(2):133-8. doi: 10.1002/hup.1097.

PMID:
20196182
8.

Dietary status and impact of risperidone on nutritional balance in children with autism: a pilot study.

Lindsay RL, Eugene Arnold L, Aman MG, Vitiello B, Posey DJ, McDougle CJ, Scahill L, Pachler M, McCracken JT, Tierney E, Bozzolo D.

J Intellect Dev Disabil. 2006 Dec;31(4):204-9.

PMID:
17178532
9.

A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders.

McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH.

Arch Gen Psychiatry. 1998 Jul;55(7):633-41.

PMID:
9672054
10.

A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone.

Masi G, Cosenza A, Mucci M, Brovedani P.

J Clin Psychiatry. 2003 Sep;64(9):1039-47.

PMID:
14628979
11.

Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia.

Popovic V, Doknic M, Maric N, Pekic S, Damjanovic A, Miljic D, Popovic S, Miljic N, Djurovic M, Jasovic-Gasic M, Dieguez C, Casanueva FF.

Neuroendocrinology. 2007;85(4):249-56.

PMID:
17570902
12.

The effect of long-term use of risperidone on body weight of children with an autism spectrum disorder.

Demb H, Valicenti-McDermott M, Navarro A, Ayoob KT.

J Clin Psychopharmacol. 2011 Oct;31(5):669-70. doi: 10.1097/JCP.0b013e31822befa9. No abstract available.

PMID:
21881456
13.

Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications.

Gagliano A, Germanò E, Pustorino G, Impallomeni C, D'Arrigo C, Calamoneri F, Spina E.

J Child Adolesc Psychopharmacol. 2004 Spring;14(1):39-47.

PMID:
15142390
14.

Iron homeostasis during risperidone treatment in children and adolescents.

Calarge CA, Ziegler EE, Del Castillo N, Aman M, McDougle CJ, Scahill L, McCracken JT, Arnold LE.

J Clin Psychiatry. 2015 Nov;76(11):1500-5. doi: 10.4088/JCP.14m09258.

PMID:
26301448
15.

Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy.

Luby J, Mrakotsky C, Stalets MM, Belden A, Heffelfinger A, Williams M, Spitznagel E.

J Child Adolesc Psychopharmacol. 2006 Oct;16(5):575-87.

PMID:
17069546
16.

Effects of short- and long-term risperidone treatment on prolactin levels in children with autism.

Anderson GM, Scahill L, McCracken JT, McDougle CJ, Aman MG, Tierney E, Arnold LE, Martin A, Katsovich L, Posey DJ, Shah B, Vitiello B.

Biol Psychiatry. 2007 Feb 15;61(4):545-50.

PMID:
16730335
17.

Rate of weight gain and cardiometabolic abnormalities in children and adolescents.

Calarge CA, Xie D, Fiedorowicz JG, Burns TL, Haynes WG.

J Pediatr. 2012 Dec;161(6):1010-5. doi: 10.1016/j.jpeds.2012.05.051.

PMID:
22738944
18.

Leptin gene -2548G/A variants predict risperidone-associated weight gain in children and adolescents.

Calarge CA, Ellingrod VL, Zimmerman B, Acion L, Sivitz WI, Schlechte JA.

Psychiatr Genet. 2009 Dec;19(6):320-7.

PMID:
19873684
19.

Acute and long-term safety and tolerability of risperidone in children with autism.

Aman MG, Arnold LE, McDougle CJ, Vitiello B, Scahill L, Davies M, McCracken JT, Tierney E, Nash PL, Posey DJ, Chuang S, Martin A, Shah B, Gonzalez NM, Swiezy NB, Ritz L, Koenig K, McGough J, Ghuman JK, Lindsay RL.

J Child Adolesc Psychopharmacol. 2005 Dec;15(6):869-84.

PMID:
16379507
20.

Antipsychotic-induced weight gain: bipolar disorder and leptin.

McIntyre RS, Mancini DA, Basile VS, Srinivasan J, Kennedy SH.

J Clin Psychopharmacol. 2003 Aug;23(4):323-7.

PMID:
12920406
Items per page

Supplemental Content

Support Center